Cargando…

Clinical Feasibility of Speech Phenotyping for Remote Assessment of Neurodegenerative and Psychiatric Disorders (RHAPSODY): a study protocol

INTRODUCTION: The diagnosis of neurodegenerative and psychiatric disorders (NPDs) in primary care can suffer from inefficiencies resulting in misdiagnoses and delayed diagnosis, limiting effective treatment options. The development of speech and language-based profiling biomarkers could aid in achie...

Descripción completa

Detalles Bibliográficos
Autores principales: Taylor, R., Hampsey, E., Mészáros, M., Skirrow, C., Strawbridge, R., Chok, L., Aarsland, D., Al-Chalabi, A., Chaudhuri, K.R., Weston, J., Fristed, E., Young, A., Awogbemila, O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9565207/
http://dx.doi.org/10.1192/j.eurpsy.2022.435
_version_ 1784808831846449152
author Taylor, R.
Hampsey, E.
Mészáros, M.
Skirrow, C.
Strawbridge, R.
Chok, L.
Aarsland, D.
Al-Chalabi, A.
Chaudhuri, K.R.
Weston, J.
Fristed, E.
Young, A.
Awogbemila, O.
author_facet Taylor, R.
Hampsey, E.
Mészáros, M.
Skirrow, C.
Strawbridge, R.
Chok, L.
Aarsland, D.
Al-Chalabi, A.
Chaudhuri, K.R.
Weston, J.
Fristed, E.
Young, A.
Awogbemila, O.
author_sort Taylor, R.
collection PubMed
description INTRODUCTION: The diagnosis of neurodegenerative and psychiatric disorders (NPDs) in primary care can suffer from inefficiencies resulting in misdiagnoses and delayed diagnosis, limiting effective treatment options. The development of speech and language-based profiling biomarkers could aid in achieving earlier motor diagnosis for PD for instance, or more accurate diagnosis of clinically similar or late presenting NPDs. OBJECTIVES: RHAPSODY aims to investigate the feasibility of the remote administration of a battery of speech tasks in eliciting continuous narrative speech across a range of NPDs. The project also aims to determine the feasibility of using acoustic and linguistic biomarkers from speech data to support the clinical assessment and disambiguation of common NPDs METHODS: All participants (n=250) will take part in a single virtual telemedicine video conference with a researcher in which they are screened and complete a battery of speech tasks, in addition to cohort-specific screening measures. Over the following month, participants will be asked to complete a series of short, self-administered speech assessments via a smartphone application. RESULTS: The speech tasks will be audio-recorded and analysed on Novoic’s technology platform. Objectives will be analysed using measures including average length of speech elicitation for speech tasks, intra- and inter-subject variance, differences in linguistic patterns, and response rates to speech assessments. CONCLUSIONS: The analyses could help to identify and validate speech-derived clinical biomarkers to support clinicians in detecting and disambiguating between NPDs with heterogeneous presentations. This should further support earlier intervention, improved treatment options and improved quality of life. DISCLOSURE: In terms of significant financial interest and relationships, it is emphasised that the private organisation Novoic, who aim to develop speech algorithms for diagnostic use, is the study’s sponsor and employees or former employees of this company comprise
format Online
Article
Text
id pubmed-9565207
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-95652072022-10-17 Clinical Feasibility of Speech Phenotyping for Remote Assessment of Neurodegenerative and Psychiatric Disorders (RHAPSODY): a study protocol Taylor, R. Hampsey, E. Mészáros, M. Skirrow, C. Strawbridge, R. Chok, L. Aarsland, D. Al-Chalabi, A. Chaudhuri, K.R. Weston, J. Fristed, E. Young, A. Awogbemila, O. Eur Psychiatry Abstract INTRODUCTION: The diagnosis of neurodegenerative and psychiatric disorders (NPDs) in primary care can suffer from inefficiencies resulting in misdiagnoses and delayed diagnosis, limiting effective treatment options. The development of speech and language-based profiling biomarkers could aid in achieving earlier motor diagnosis for PD for instance, or more accurate diagnosis of clinically similar or late presenting NPDs. OBJECTIVES: RHAPSODY aims to investigate the feasibility of the remote administration of a battery of speech tasks in eliciting continuous narrative speech across a range of NPDs. The project also aims to determine the feasibility of using acoustic and linguistic biomarkers from speech data to support the clinical assessment and disambiguation of common NPDs METHODS: All participants (n=250) will take part in a single virtual telemedicine video conference with a researcher in which they are screened and complete a battery of speech tasks, in addition to cohort-specific screening measures. Over the following month, participants will be asked to complete a series of short, self-administered speech assessments via a smartphone application. RESULTS: The speech tasks will be audio-recorded and analysed on Novoic’s technology platform. Objectives will be analysed using measures including average length of speech elicitation for speech tasks, intra- and inter-subject variance, differences in linguistic patterns, and response rates to speech assessments. CONCLUSIONS: The analyses could help to identify and validate speech-derived clinical biomarkers to support clinicians in detecting and disambiguating between NPDs with heterogeneous presentations. This should further support earlier intervention, improved treatment options and improved quality of life. DISCLOSURE: In terms of significant financial interest and relationships, it is emphasised that the private organisation Novoic, who aim to develop speech algorithms for diagnostic use, is the study’s sponsor and employees or former employees of this company comprise Cambridge University Press 2022-09-01 /pmc/articles/PMC9565207/ http://dx.doi.org/10.1192/j.eurpsy.2022.435 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Taylor, R.
Hampsey, E.
Mészáros, M.
Skirrow, C.
Strawbridge, R.
Chok, L.
Aarsland, D.
Al-Chalabi, A.
Chaudhuri, K.R.
Weston, J.
Fristed, E.
Young, A.
Awogbemila, O.
Clinical Feasibility of Speech Phenotyping for Remote Assessment of Neurodegenerative and Psychiatric Disorders (RHAPSODY): a study protocol
title Clinical Feasibility of Speech Phenotyping for Remote Assessment of Neurodegenerative and Psychiatric Disorders (RHAPSODY): a study protocol
title_full Clinical Feasibility of Speech Phenotyping for Remote Assessment of Neurodegenerative and Psychiatric Disorders (RHAPSODY): a study protocol
title_fullStr Clinical Feasibility of Speech Phenotyping for Remote Assessment of Neurodegenerative and Psychiatric Disorders (RHAPSODY): a study protocol
title_full_unstemmed Clinical Feasibility of Speech Phenotyping for Remote Assessment of Neurodegenerative and Psychiatric Disorders (RHAPSODY): a study protocol
title_short Clinical Feasibility of Speech Phenotyping for Remote Assessment of Neurodegenerative and Psychiatric Disorders (RHAPSODY): a study protocol
title_sort clinical feasibility of speech phenotyping for remote assessment of neurodegenerative and psychiatric disorders (rhapsody): a study protocol
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9565207/
http://dx.doi.org/10.1192/j.eurpsy.2022.435
work_keys_str_mv AT taylorr clinicalfeasibilityofspeechphenotypingforremoteassessmentofneurodegenerativeandpsychiatricdisordersrhapsodyastudyprotocol
AT hampseye clinicalfeasibilityofspeechphenotypingforremoteassessmentofneurodegenerativeandpsychiatricdisordersrhapsodyastudyprotocol
AT meszarosm clinicalfeasibilityofspeechphenotypingforremoteassessmentofneurodegenerativeandpsychiatricdisordersrhapsodyastudyprotocol
AT skirrowc clinicalfeasibilityofspeechphenotypingforremoteassessmentofneurodegenerativeandpsychiatricdisordersrhapsodyastudyprotocol
AT strawbridger clinicalfeasibilityofspeechphenotypingforremoteassessmentofneurodegenerativeandpsychiatricdisordersrhapsodyastudyprotocol
AT chokl clinicalfeasibilityofspeechphenotypingforremoteassessmentofneurodegenerativeandpsychiatricdisordersrhapsodyastudyprotocol
AT aarslandd clinicalfeasibilityofspeechphenotypingforremoteassessmentofneurodegenerativeandpsychiatricdisordersrhapsodyastudyprotocol
AT alchalabia clinicalfeasibilityofspeechphenotypingforremoteassessmentofneurodegenerativeandpsychiatricdisordersrhapsodyastudyprotocol
AT chaudhurikr clinicalfeasibilityofspeechphenotypingforremoteassessmentofneurodegenerativeandpsychiatricdisordersrhapsodyastudyprotocol
AT westonj clinicalfeasibilityofspeechphenotypingforremoteassessmentofneurodegenerativeandpsychiatricdisordersrhapsodyastudyprotocol
AT fristede clinicalfeasibilityofspeechphenotypingforremoteassessmentofneurodegenerativeandpsychiatricdisordersrhapsodyastudyprotocol
AT younga clinicalfeasibilityofspeechphenotypingforremoteassessmentofneurodegenerativeandpsychiatricdisordersrhapsodyastudyprotocol
AT awogbemilao clinicalfeasibilityofspeechphenotypingforremoteassessmentofneurodegenerativeandpsychiatricdisordersrhapsodyastudyprotocol